Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1693-1703

  Todd, Sarah Katrina ^a   Pepper, Ruth J ^a   Draibe, Juliana ^a   Tanna, Anisha ^b   Pusey, Charles D ^b   Mauri, Claudia ^c   Salama, Alan D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ANCA associated vasculitis; B lymphocyte subsets; B regulatory cells

Indexed keywords

CD24 ANTIGEN; CD38 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; METHOTREXATE; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

ACUTE DISEASE; ANCA ASSOCIATED VASCULITIS; ANTIGEN EXPRESSION; ARTICLE; B CELL CULTURE; B LYMPHOCYTE; CELL POPULATION; COCULTURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; REMISSION; T CELL CULTURE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 84906825667     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu136     Document Type: Article

References (37)

1. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006;17:1235-42.
2. Guerry MJ, Brogan P, Bruce IN et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2012;51: 634-43.
3. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
4. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005;238:67-75.
5. Harris DP, Haynes L, Sayles PC et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
6. Palanichamy A, Barnard J, Zheng B et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009;182:5982-93.
7. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev 2004; 197:179-91.
8. Blair PA, Norena LY, Flores-Borja F et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32:129-40.
9. Iwata Y, Matsushita T, Horikawa M et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011;117: 530-41.
10. Jennette J, Falk R, Bacon P, Basu N et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65: 1-11.
11. Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008;20:67-82.
12. Flores-Borja F, Bosma A, Ng D et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 2013;5: 173ra23.
13. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995;188: 117-28.
14. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23.
15. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8.
16. Lamprecht P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin Exp Immunol 2005;141:201-10.
17. Duddy M, Niino M, Adatia F et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178: 6092-9.
18. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:705-10.
19. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 2012;14:R32.
20. Kessel A, Haj T, Peri R, Snir A et al. Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 2012;11: 670-7.
21. Bouaziz JD, Calbo S, Maho-Vaillant M et al. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol 2010;40: 2686-91.
22. Wei C, Anolik J, Cappione A et al. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007;178: 6624-33.
23. Morva A, Lemoine S, Achour A et al. Maturation and function of human dendritic cells are regulated by B lymphocytes. Blood 2012;119:106-14.
24. van de Veen W, Stanic B, Yaman G et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013;131: 1204-12.
25. Amu S, Tarkowski A, Dorner T et al. The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol 2007;66: 77-86.
26. Eriksson P, Sandell C, Backteman K, Ernerudh J. B cell abnormalities in Wegener's granulomatosis and microscopic polyangiitis: role of CD25+-expressing B cells. J Rheumatol 2010;37:2086-95.
27. Thiel J, Salzer U, Hässler F et al. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity 2013; 1-10.
28. Bunch DO, McGregor JG, Khandoobhai NB et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013;8: 382-91.
29. Wilde B, Thewissen M, Van Paassen P et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013; 72:1416-9.
30. Tadema H, Abdulahad WH, Lepse N et al. Bacterial DNA motifs trigger ANCA production in ANCAassociated vasculitis in remission. Rheumatology 2011;50: 689-96.
31. Cuss AK, Avery DT, Cannons JL et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol 2006;176: 1506-16.
32. Langkjaer A, Kristensen B, Hansen BE et al. B-cell exposure to self-antigen induces IL-10 producing B cells as well as IL-6- and TNF-alpha-producing B-cell subsets in healthy humans. Clin Immunol 2012;145: 1-10.
33. Yoshizaki A, Miyagaki T, DiLillo DJ et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012;491: 264-8.
34. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009;182: 7459-72.
35. Matsumoto M, Fujii Y, Baba A, Kurosaki T, Baba Y. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. Immunity 2011;34:703-14.
36. Hussain S, Delovitch TL. Intravenous transfusion of BCRactivated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 2007;179: 7225-32.
37. Yanaba K, Bouaziz JD, Haas KM et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28:639-50.